We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of 41 cents, which surpassed the Zacks Consensus Estimate by 24.24%. Envista’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.41%.
Q3 Estimates for NVST
The Zacks Consensus Estimate for revenues is pegged at $686.3 million, which suggests an increase of 2.5% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pinned at 35 cents, indicating a year-over-year increase of 9.4%. The estimate has moved south 1 cent in the past 60 days.
Here’s a quick overview of the company’s performance prior to the announcement.
Key Factors Likely to Have Driven NVST’s Q3 Performance
In the third quarter, Envista is likely to have delivered balanced growth across both reporting segments, Specialty Products & Technologies and Equipment & Consumables, and all major geographies.
The Specialty Products & Technologies business is likely to have benefited from continued improvement in orthodontics, led by strong growth in Spark aligners. The expansion of OrmcoDigital Bonding (“ODB”) to all bracket systems in the previous quarter is also expected to have supported growth by strengthening Envista’s comprehensive orthodontic offerings. Meanwhile, implant core sales are likely to have remained stable, with well balanced growth across geographic markets.
Equipment & Consumables is likely to have benefited from broad-based growth across consumables and diagnostics businesses. Consumables growth might have been aided by continued innovation and favorable pricing. In line with this, Envista had two notable launches in the consumables business — ZenSeal Pro and DemiPro.
Envista Holdings Corporation Price and EPS Surprise
ZenSeal Pro is an all-in-one bioceramic endodontic sealer, while DemiPro is a lightweight cordless curing light used across many restorative dental procedures. Meanwhile, strong diagnostic sales in North America, driven by above-market growth, might have further boosted the third-quarter performance. The ongoing innovation in equipment and software, alongside growth in services, is expected to have supported demand for comprehensive customer solutions.
The company is benefiting from the Envista Business System. During the previous quarter, improving manufacturing productivity helped drive gross margin expansion and when combined with sustained G&A productivity, adjusted EBITDA margin expanded 230 basis points. It further reduced effective tax rate, contributing to the very strong EPS growth. We expect this trend to have persisted in the to-be-reported quarter as well.
What Our Model Suggests for NVST
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: Envista has an Earnings ESP of -0.48%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Envista Q3 Earnings Ahead: Product Innovation to Drive Growth
Key Takeaways
Envista (NVST - Free Report) is scheduled to release third-quarter 2026 results on Nov. 4, after the closing bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of 41 cents, which surpassed the Zacks Consensus Estimate by 24.24%. Envista’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.41%.
Q3 Estimates for NVST
The Zacks Consensus Estimate for revenues is pegged at $686.3 million, which suggests an increase of 2.5% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pinned at 35 cents, indicating a year-over-year increase of 9.4%. The estimate has moved south 1 cent in the past 60 days.
Here’s a quick overview of the company’s performance prior to the announcement.
Key Factors Likely to Have Driven NVST’s Q3 Performance
In the third quarter, Envista is likely to have delivered balanced growth across both reporting segments, Specialty Products & Technologies and Equipment & Consumables, and all major geographies.
The Specialty Products & Technologies business is likely to have benefited from continued improvement in orthodontics, led by strong growth in Spark aligners. The expansion of OrmcoDigital Bonding (“ODB”) to all bracket systems in the previous quarter is also expected to have supported growth by strengthening Envista’s comprehensive orthodontic offerings. Meanwhile, implant core sales are likely to have remained stable, with well balanced growth across geographic markets.
Equipment & Consumables is likely to have benefited from broad-based growth across consumables and diagnostics businesses. Consumables growth might have been aided by continued innovation and favorable pricing. In line with this, Envista had two notable launches in the consumables business — ZenSeal Pro and DemiPro.
Envista Holdings Corporation Price and EPS Surprise
Envista Holdings Corporation price-eps-surprise | Envista Holdings Corporation Quote
ZenSeal Pro is an all-in-one bioceramic endodontic sealer, while DemiPro is a lightweight cordless curing light used across many restorative dental procedures. Meanwhile, strong diagnostic sales in North America, driven by above-market growth, might have further boosted the third-quarter performance. The ongoing innovation in equipment and software, alongside growth in services, is expected to have supported demand for comprehensive customer solutions.
The company is benefiting from the Envista Business System. During the previous quarter, improving manufacturing productivity helped drive gross margin expansion and when combined with sustained G&A productivity, adjusted EBITDA margin expanded 230 basis points. It further reduced effective tax rate, contributing to the very strong EPS growth. We expect this trend to have persisted in the to-be-reported quarter as well.
What Our Model Suggests for NVST
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: Envista has an Earnings ESP of -0.48%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.